| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 13, 2026 11:30 A.M. |
| Form: | S-1 | ||||||
| |||||||
SEC EDGARFiled Feb 17, 2026 - 12:15 AM ET
Liminatus Pharma, Inc. S-1 registration statement effective
LIMN Price
Chart unavailableN/A$0.00 (+0.00%)
Chart unavailable
Dilution Snapshot
Current shares26,833,407 sharesLatest available market context.
Registered sharesNot disclosedPotential supply.
Supply / currentNot disclosedCalculated only when share counts are disclosed.
Company proceedsNot disclosedCompany proceeds were not clearly disclosed.
Effectiveness of a S-1 registration statement can allow registered issuance or resale activity under the related registration filing
The follow-up risk is whether more supply becomes eligible. The filing also points to possible overhang outside the current pool. Next trigger: Linked analysis for the original registration filing
Share Overhang
Current shares plus potential supply
Needs reviewNo supply countTotal potential dilution vs. current shares
Current Shares Outstanding26.83M
Registered SharesNot disclosed
Potential supply was not disclosed or mechanically calculable, so share overhang is not calculated.
Share counts are filing-stated unless noted and may differ after splits, conversions, or later offerings.
Supply Details
Current Shares Outstanding26.83M
Registered SharesNot disclosed
Total OverhangNot disclosed
Overhang LevelNeeds review
Breakdown
% of currentHigh share overhang may create selling pressure. Monitor warrant exercise and note conversion activity.
LIMN Market Context
SectorHealthcare
IndustryBiotechnology
Market Cap$3.80M
Shares Outstanding26.83M
Public Float8.07M
Public Float %30.1%
Original Filing Text
SEC filing text preserved from the raw item store.
| Form | EFFECT |
|---|---|
| Normalized event type | Dilution Risk |